From Data to Decisions: Real-World Case Studies in Personalized GLP-1 RA Therapy for T2D

Faculty

Amy E. Rothberg, MD, DABOM
Clinical Professor of Medicine, Division of Metabolism, Endocrinology & Diabetes
Department of Internal Medicine
Research Professor of Nutritional Sciences, School of Public Health
Director, Weight Management Program & Rewind
University of Michigan
Ann Arbor, MI
Jay H. Shubrook, DO, FAAFP, FACOFP
Professor, Diabetologist
Department of Clinical Sciences and Community Health
Touro University California
Vallejo, CA

Statement of Need

GLP-1 receptor agonists (GLP-1 RAs) are revolutionizing glycemic control for patients with type 2 diabetes (T2D), but with rising clinical complexity and diverse patient needs, a one-size-fits-all approach is insufficient. While every currently available GLP-1 RA is indicated for blood sugar management in patients with T2D, emerging evidence shows that certain agents offer distinct advantages – particularly for patients with cardiovascular disease (CVD), chronic kidney disease (CKD), or a mix of comorbidities. This critical data frequently remains untapped in real-world treatment plans, however, resulting in missed opportunities to deliver the most effective, personalized care. Clinicians and multidisciplinary care teams need next-level education that translates robust clinical trial evidence into targeted, patient-first decisions, maximizing the therapeutic potential of each GLP-1 RA and elevating outcomes across the T2D population.

In the third activity of this CME Outfitters Snack series, expert faculty will incorporate clinical trial evidence supporting the use of GLP-1 RAs in T2D management, including outcomes related to glucose control, CV safety, CKD, and tolerability. Faculty will model utilization of current treatment guidelines to implement GLP-1 RA therapy tailored to individual patient characteristics, including comorbidities, goals of care, and lifestyle considerations.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Incorporate clinical trial evidence supporting the use of GLP-1 RAs in T2D management, including outcomes related to glucose control, CV safety, CKD, and tolerability
  • Utilize current treatment guidelines to implement GLP-1 RA therapy tailored to individual patient characteristics, including comorbidities, goals of care, and lifestyle considerations

Financial Support

Supported by an educational grant from Novo Nordisk Inc.

Target Audience

Primary care physicians (PCPs), physician associates (PAs), nurse practitioners (NPs), and pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 0.75

CME Outfitters, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists (ACPE) 0.75

This application-based activity is approved for 0.75 contact hours (0.075 CEUs) of continuing pharmacy credit (JA0007185-0000-25-067-H01-P).

Nurses (ANCC) 0.75

This activity is designated for 0.75 contact hours.

California Residents: Provider approved by the California Board of Registered Nursing, Provider # CEP 15510, for 0.75 Contact Hours.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Physician Assistants (AAPA): 0.75

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 09/11/2026. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.75

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Rothberg reports the following financial relationships:

Grants: Boehringer Ingelheim

Dr. Shubrook reports the following financial relationships:

Advisory Board: Abbott; Bayer; Insulet Corporation; Lilly; Madrigal Pharmaceuticals, Inc.; Novo Nordisk; and Sanofi

Consultant: Abbott; Bayer; Novo Nordisk; and Sanofi

Grants: Breakthrough T1D

The following individuals have no financial relationships to disclose:

Thai Nguyen, MD, MHA (Peer Reviewer)
Jessica Giddens, DNP, APRN, FPMHNP-BC, RN-BC (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
Carrie Allen, PharmD, BCPS (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

SN-270-091125-68

From Data to Decisions: Real-World Case Studies in Personalized GLP-1 RA Therapy for T2D
Event Date: 09/11/2025